相关实验视频

Updated: Apr 12, 2026

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management

Published on: November 21, 2017

心血管内冷却试验 (CHILL-SHOCK) 的心血管冲击试验

Nikhil Gupta¹, Rohan J Kalathiya², Nikhil Singh³

¹Department of Medicine, University of Chicago, Chicago, IL.

Journal of cardiac failure

|March 8, 2024

概括

针对性温度控制 (TTC) 对于心脏性休克 (CS) 患者来说似乎是安全的. 这种疗法可以改善血液动力学功能而不会增加不良事件,为CS提供潜在的新疗法.

科学领域:

心脏病学心脏病学
关键护理医学关键护理医学
治疗性低温症治疗性低温症

背景情况:

心脏性休克 (CS) 与高死亡率有关.
针对性温度控制 (TTC) 正在作为CS的潜在辅助疗法进行研究.
在CS患者中TTC的安全性需要彻底检查.

研究的目的:

评估针对性温度控制 (TTC) 作为心脏性休克 (CS) 患者的辅助治疗的安全性.
评估TTC对CS患者血液动力学参数和死亡率的影响.

主要方法:

一个开放的,随机控制的试验试验,涉及20名CS患者.
患者被分配到标准护理加TTC或单独标准护理.
主要结局是综合安全性评估;次要结局包括死亡率,血液动力学测量和异能剂使用.

主要成果:

在TTC和对照组之间的预规定的安全结果没有显著差异 (3事件对0事件,P=0.24).
接受TTC治疗的患者在48-96小时内显示心脏指数和心脏功率指数的统计学上显著改善.
观察到心脏指数 (3.6比2.6L/分钟/米2;P=0.029) 和心脏功率指数 (0.61比0.53W/米2;P=0.029) 的改善.

结论:

针对性温度控制 (TTC) 可能是心脏性休克 (CS) 患者的安全辅助疗法.
在CS患者中,TTC显示出改善关键血液动力学参数的潜力.
需要进一步的研究来证实TTC在CS管理中的好处和安全性.

关键词:

心脏衰竭是因为心脏衰竭.心脏发生的冲击是心脏发生的冲击.关键护理关键护理的关键护理诱导低温导致的低温.

更多相关视频

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms

Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms

Published on: March 3, 2021

相关概念视频

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...